Dragonfly: Dragonfly Therapeutics, Inc.: Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET Dose Escalation Results at ASCO 2023 Annual Meeting

In the ASCO Developmental Therapeutics - Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly's phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 in ...